Episurf Medical AB Class B

As of June 30, 2026, Episurf Medical AB Class B carries a market capitalization of 589.12M, placing it among publicly traded companies globally. Its enterprise value stands at 851.82M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Episurf Medical AB Class B's next confirmed earnings release is scheduled for November 20, 2026.

As of June 30, 2026, Episurf Medical AB Class B has 6.93B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 9.17, and the price-to-book ratio stands at 0.98.

These figures are as of June 30, 2026. The EV/Sales ratio of 40.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 851.82M versus a market cap of 589.12M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Episurf Medical AB Class B maintains a current ratio of 2.45, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 104.44, indicating elevated leverage, while an interest coverage ratio of -1.57 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Episurf Medical AB Class B posted a negative return on equity (ROE) of -73.86, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -31.50, reflecting losses generated across the asset base. The company generates approximately 1.01M in revenue per employee across its workforce of 21.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Episurf Medical AB Class B recorded an income tax benefit of -700,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -246.80M and -246.00M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Episurf Medical AB Class B's stock has gained approximately 91.52% over the past 52 weeks. The 50-day moving average sits at 0.07, while the 200-day moving average is 0.07.

Over the twelve months ended June 30, 2026, Episurf Medical AB Class B generated 21.20M in revenue and converted that into -246.00M in net income, yielding earnings per share of -0.11. EBITDA reached -23.20M, while operating income came in at -61.00M.

As of June 30, 2026, Episurf Medical AB Class B holds 362.80M in cash and equivalents against 625.50M in total debt, resulting in a net debt position of 591.70M. Total book value stands at 598.90M, with working capital of 237.70M providing operational flexibility.

Episurf Medical AB Class B produced 20.50M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -7.80M in capital expenditures, free cash flow totaled 12.70M - equivalent to 0.01 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -287.74 and net profit margin of -1,160.38 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 6.53, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.70, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Episurf Medical AB Class B shareholders.

Episurf Medical AB Class B's most recent stock split took place on August 5, 2025 with a 1000:1467 split ratio.